195 related articles for article (PubMed ID: 11129170)
1. ZD1839 ('Iressa') as an anticancer agent.
Baselga J; Averbuch SD
Drugs; 2000; 60 Suppl 1():33-40; discussion 41-2. PubMed ID: 11129170
[TBL] [Abstract][Full Text] [Related]
2. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells.
Di Gennaro E; Barbarino M; Bruzzese F; De Lorenzo S; Caraglia M; Abbruzzese A; Avallone A; Comella P; Caponigro F; Pepe S; Budillon A
J Cell Physiol; 2003 Apr; 195(1):139-50. PubMed ID: 12599217
[TBL] [Abstract][Full Text] [Related]
3. ZD1839: targeting the epidermal growth factor receptor in cancer therapy.
Herbst RS
Expert Opin Investig Drugs; 2002 Jun; 11(6):837-49. PubMed ID: 12036427
[TBL] [Abstract][Full Text] [Related]
4. Phase I studies of ZD1839 in patients with common solid tumors.
Lorusso PM
Semin Oncol; 2003 Feb; 30(1 Suppl 1):21-9. PubMed ID: 12644981
[TBL] [Abstract][Full Text] [Related]
5. Gefitinib, a novel, orally administered agent for the treatment of cancer.
Ranson M; Wardell S
J Clin Pharm Ther; 2004 Apr; 29(2):95-103. PubMed ID: 15068398
[TBL] [Abstract][Full Text] [Related]
6. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.
Baselga J; Rischin D; Ranson M; Calvert H; Raymond E; Kieback DG; Kaye SB; Gianni L; Harris A; Bjork T; Averbuch SD; Feyereislova A; Swaisland H; Rojo F; Albanell J
J Clin Oncol; 2002 Nov; 20(21):4292-302. PubMed ID: 12409327
[TBL] [Abstract][Full Text] [Related]
7. Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
Von Pawel J
Bull Cancer; 2004 May; 91(5):E70-6. PubMed ID: 15582898
[TBL] [Abstract][Full Text] [Related]
8. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients.
Herbst RS
Semin Oncol; 2003 Feb; 30(1 Suppl 1):30-8. PubMed ID: 12644982
[TBL] [Abstract][Full Text] [Related]
9. ZD1839 (Iressa) in non-small-cell lung cancer.
Herbst RS; Khuri FR; Fossella FV; Glisson BS; Kies MS; Pisters KM; Riddle JR; Terry KA; Lee JS
Clin Lung Cancer; 2001 Aug; 3(1):27-32. PubMed ID: 14656386
[TBL] [Abstract][Full Text] [Related]
10. Anti-EGF receptor therapy.
Blackledge G; Averbuch S; Kay A; Barton J
Prostate Cancer Prostatic Dis; 2000 Dec; 3(4):296-302. PubMed ID: 12497082
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
12. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer.
Raben D; Helfrich BA; Chan D; Johnson G; Bunn PA
Semin Oncol; 2002 Feb; 29(1 Suppl 4):37-46. PubMed ID: 11894012
[TBL] [Abstract][Full Text] [Related]
13. Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells.
Sgambato A; Camerini A; Faraglia B; Ardito R; Bianchino G; Spada D; Boninsegna A; Valentini V; Cittadini A
J Cell Physiol; 2004 Oct; 201(1):97-105. PubMed ID: 15281092
[TBL] [Abstract][Full Text] [Related]
14. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa).
Heimberger AB; Learn CA; Archer GE; McLendon RE; Chewning TA; Tuck FL; Pracyk JB; Friedman AH; Friedman HS; Bigner DD; Sampson JH
Clin Cancer Res; 2002 Nov; 8(11):3496-502. PubMed ID: 12429640
[TBL] [Abstract][Full Text] [Related]
15. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
Janmaat ML; Kruyt FA; Rodriguez JA; Giaccone G
Clin Cancer Res; 2003 Jun; 9(6):2316-26. PubMed ID: 12796401
[TBL] [Abstract][Full Text] [Related]
16. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.
Wakeling AE; Guy SP; Woodburn JR; Ashton SE; Curry BJ; Barker AJ; Gibson KH
Cancer Res; 2002 Oct; 62(20):5749-54. PubMed ID: 12384534
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracil.
Magné N; Fischel JL; Tiffon C; Formento P; Dubreuil A; Renée N; Formento JL; Francoual M; Ciccolini J; Etienne MC; Milano G
Br J Cancer; 2003 Aug; 89(3):585-92. PubMed ID: 12888834
[TBL] [Abstract][Full Text] [Related]
18. Studies with ZD1839 in preclinical models.
Sirotnak FM
Semin Oncol; 2003 Feb; 30(1 Suppl 1):12-20. PubMed ID: 12644980
[TBL] [Abstract][Full Text] [Related]
19. ZD1839 (Iressa): for more than just non-small cell lung cancer.
Ranson M
Oncologist; 2002; 7 Suppl 4():16-24. PubMed ID: 12202784
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839.
Albanell J; Rojo F; Baselga J
Semin Oncol; 2001 Oct; 28(5 Suppl 16):56-66. PubMed ID: 11706397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
